Ruxolitinib is approved for chronic graft-versus-host disease

Share This Post

October 2021: After failure of one or two lines of systemic therapy, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) in adults and children aged 12 and up.

REACH-3 (NCT03112603) compared ruxolitinib to best available therapy (BAT) in a randomised, open-label, multicenter clinical trial for corticosteroid-refractory cGVHD after allogeneic stem cell transplantation. 329 individuals (1:1) were randomly assigned to receive either ruxolitinib 10 mg twice daily or BAT in this study.

Overall response rate (ORR) (2014 NIH Response Criteria) through cycle 7 day 1 was the key efficacy result utilised to support approval. The ORR for the ruxolitinib arm was 70% (95 percent CI 63 percent, 77 percent) and the ORR for the BAT arm was 57 percent (95 percent CI 49 percent, 65 percent), a difference of 13%. (95 percent CI 3 percent , 23 percent ). The median durations of response for the ruxolitinib and BAT arms, computed from first response to progression, death, or new systemic treatments for chronic GVHD, were 4.2 months (95% CI 3.2, 6.7) and 2.1 months (95% CI 1.6, 3.2), respectively. The median durations from first response to death or new systemic therapy for cGVHD in the ruxolitinib and BAT arms were 25 months (95 percent CI 16.8, NE) and 5.6 months (95 percent CI 4.1, 7.8), respectively.

Anemia and thrombocytopenia were the most common hematologic adverse responses of ruxolitinib in patients with cGVHD (incidence > 35 percent). Infections and viral infection were the most prevalent nonhematologic side effects (incidence 20%).

For cGVHD, a beginning dose of ruxolitinib of 10 mg twice daily is indicated.

Take second opinion on Bone marrow transplant

Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy